BHCM
ANIP icon

Brevan Howard Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Brevan Howard Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Sell
2,482
-4,989
-67% -$400K ﹤0.01% 1891
2026
Q1 		$575K Sell
7,471
-14,766
-66% -$1.15M 0.01% 1216
2025
Q4 		$1.76M Buy
22,237
+10,037
+82% +$869K 0.02% 524
2025
Q3 		$1.12M Buy
+12,200
New +$995K 0.01% 843

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's ANIP Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its ANI Pharmaceuticals (ANIP) stake by 67% in Q2 2026, selling an estimated $400K and leaving 2,482 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #1891.

Brevan Howard Capital Management first reported a position in ANIP in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.76M in Q4 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Brevan Howard Capital Management held 2,482 shares of ANI Pharmaceuticals worth $205K as of Q2 2026.
  • Brevan Howard Capital Management sold 4,989 ANI Pharmaceuticals shares in Q2 2026, an estimated $400K.
  • ANI Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1891 holding.
  • Brevan Howard Capital Management first reported a position in ANI Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's ANI Pharmaceuticals position peaked at $1.76M in Q4 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.